Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy A case report

被引:8
|
作者
Wang, Li-Xin [1 ]
Chen, Xiaoping [1 ]
Jia, Mingming [2 ]
Wang, Shengdian [2 ]
Shen, Jianliang [1 ]
机构
[1] Navy Gen Hosp PLA, Dept Hematol, Beijing 100048, Peoples R China
[2] Chinese Acad Sci, Inst Biophys, Key Lab Infect & Immun, Beijing, Peoples R China
关键词
arthritis; chimeric antigen receptor (CAR)-T cell therapy; cytokine release syndrome;
D O I
10.1097/MD.0000000000010455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understanding of the clinical manifestations and pathogenesis of CRS is still limited. Patient concerns: A 34-year-old male patient was diagnosed with ALL in June 2015. Complete remission (CR) was achieved after induction chemotherapy. The patient received 8 cycles of consolidation chemotherapy to maintain CR. In May 2017, the patient had recurrent ALL. Induction chemotherapy was given again, but without remission. In October 2017, CAR-T cell therapy was given. On October 14, the patient was pretreated with an FC regimen (fludarabine phosphate 50 mg qd on days 1-3; cyclophosphamide 0.4 g qd on days 1-3). CAR-T cells were infused on October 19 and October 20, with the number of infused cells at 2 x 10(5)/kg and 1 x 10(5)/kg, respectively. On October 25, the patient had a high fever, swelling, and pain in the large joints of the limbs, and joint effusion. Diagnosis: This patient was diagnosed with relapsed ALL, and he developed CRS after CAR-T therapy. Interventions: Tacilizumab (400 mg) was infused after CRS was diagnosed, and another dose of tacilizumab (240 mg) was given 6 days later. The pain was also treated with an analgesic drug. Methylprednisolone (1 mg/kg) was given to treat arthritis of the large joints. Outcomes: The patient's temperature was back to normal within 1 hour following the treatment of tacilizumab, but the pain in the large joints was progressively aggravated. The joint swelling and pain were obviously alleviated after the treatment of methylprednisolone, and the joint mobility was gradually recovered. Lessons: CRS after CAR-T therapy can manifest as a high fever with swelling and pain in the large joints of the limbs, similar to rheumatoid arthritis. Tocilizumab can lower the body temperature, but it has no significant effect on arthritis. Glucocorticoids can rapidly alleviate joint swelling and pain.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
    Chen, Hsin-Hui
    Kuo, Cheng-Yi
    Ho, Ching-Liang
    Chen, Yeu-Chin
    MEDICINE, 2023, 102 (41) : E35432
  • [22] Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches
    Shin, Yunjung H.
    Tian, Xiaofan
    Park, Jiyeon J.
    Kim, Gee Y.
    Aboujaoude, Emily
    Sturgill, Marc G.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 159 - 174
  • [23] Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
    Hu, Yongxian
    Sun, Jie
    Wu, Zhao
    Yu, Jian
    Cui, Qu
    Pu, Chengfei
    Liang, Bin
    Luo, Yi
    Shi, Jimin
    Jin, Aiyun
    Xiao, Lei
    Huang, He
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [24] Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
    Yongxian Hu
    Jie Sun
    Zhao Wu
    Jian Yu
    Qu Cui
    Chengfei Pu
    Bin Liang
    Yi Luo
    Jimin Shi
    Aiyun Jin
    Lei Xiao
    He Huang
    Journal of Hematology & Oncology, 9
  • [25] CT Demonstration of Local Cytokine-Release Syndrome Involving the Head and Neck Following Chimeric Antigen Receptor T Cell Infusion Therapy
    Ko, Ji Su
    Lee, Jeong Hyun
    Yoon, Dok Hyun
    Suh, Chong Hyun
    Chung, Sae Rom
    Choi, Young Jun
    Baek, Jung Hwan
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (04) : 399 - 402
  • [26] Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR) - T-Cell therapy
    Hoyt, Robert
    Ye, Zhan
    Dasgupta, Amitava
    CLINICA CHIMICA ACTA, 2024, 559
  • [27] Chimeric antigen receptor T cell therapy comes to clinical practice
    Wall, D. A.
    Krueger, J.
    CURRENT ONCOLOGY, 2020, 27 : S115 - S123
  • [28] Efficacy of emapalumab in the management of anti-CD19 chimeric antigen receptor T-cell therapy-associated cytokine release syndrome: A report of two cases
    Cai, Wenzhi
    Lu, Yutong
    He, Haiju
    Li, Jiaqi
    Liu, Shuangzhu
    Geng, Hongzhi
    Yang, Qin
    Zeng, Liangyu
    Wu, Depei
    Li, Caixia
    ONCOLOGY LETTERS, 2025, 29 (02)
  • [29] Severe cases of local cytokine release syndrome (CRS); craniocervical edema soon after chimeric antigen T-cell (CAR-T) therapy
    Nakamura, Naokazu
    Jo, Tomoyasu
    Arai, Yasuyuki
    Kitawaki, Toshio
    Nishikori, Momoko
    Mizumoto, Chisaki
    Kanda, Junya
    Yamashita, Kouhei
    Nagao, Miki
    Takaori-Kondo, Akifumi
    OXFORD MEDICAL CASE REPORTS, 2025, 2025 (01):
  • [30] Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden
    Patel, Rushin
    Patel, Mrunal
    Laxmidhar, Fehmida
    Lakhatariya, Khushboo
    Patel, Darshil
    Patel, Zalak
    Shaikh, Safia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)